Search The Medical Knowledge Base

Drug Details

ELLESTE SOLO MX

• Drug Class Description
  Oestrogens.
• Generic Name
  Estradiol [oestradiol]
• Presentation
  Elleste Solo MX 80: Estradiol 80 microgram per 24 hours. Elleste Solo MX 40: Estradiol 40 microgram per 24 hours.
• Description
  Elleste Solo MX 80: transdermal matrix patch. Elleste Solo MX 40: transdermal matrix patch.
• Indications
  Elleste Solo MX 80: HRT for menopausal oestrogen deficiency. Prevention of postmenopausal osteoporosis. Elleste Solo MX 40: HRT for menopausal oestrogen deficiency.
• Adult Dosage
  

  Apply patch to clean, non-hairy area of skin below the waist and replace with a new patch every 3 - 4 days using a different site. Menopausal symptoms, commence with 40 microgram patch. Increase to 80 microgram patch if necessary.

  Maintenance, use lowest effective dose. Postmenopausal osteoporosis, use 80 microgram patch. When a progestogen is necessary, the appropriate dose should be given for 12 - 14 days per month.

• Child Dosage
  Not applicable.
• Contra Indications
  

  Cancer of breast, genital tract or other oestrogen-dependent carcinoma, undiagnosed vaginal bleeding or endometriosis. Active thrombophlebitis or thromboembolic disorders. Severe cardiac, hepatic or renal disease. Dubin-Johnson or Rotor syndromes. Pregnancy, lactation.

• Special Precautions
  

  History or increased risk of thromboembolic disorders. Mild chronic liver disease; monitor liver function every 8 to 12 with cholelithiasis, otosclerosis, migraine, multiple sclerosis, epilepsy, diabetes, hypertension, porphyria, uterine fibroids, tetany.

  Examine blood pressure, pelvic organs and breasts (particularly those with fibrocystic disease of the breast or a family history of breast cancer) before and regularly during treatment. If breakthrough bleeding is persistent, perform endometrial assessment, which may include biopsy.

• Interactions
  Liver enzyme inducing drugs.
• Adverse Drug Reactions
  

  GI upset, nausea, vomiting, weight gain, breast tenderness and enlargement, breakthrough bleeding, headache, dizziness, impaired liver function, cholestatic jaundice, epistaxis, migraine, thromboembolic disorders, exacerbation of varicose veins, increased blood pressure, transient erythema, generalised pruritus.

  REASONS FOR IMMEDIATE DISCONTINUATION OF TREATMENT: Occurence of migraine-type headaches for the first time, frequent severe headaches, acute visual disturbances, signs of thrombophlebitis or thromboembolism, or any other possible prodromal symptoms of vascular occlusion. Rise in blood pressure. Jaundice. Pregnancy. Discontinue six weeks before major elective surgery and during immobilisation entailing risk of thrombosis.